ERRATUM TO

Chapter 15 Advances in Breast Cancer Therapy Using Nitric Oxide and Nitroxyl Donor Agents

Debashree Basudhar, Katrina M. Miranda, David A. Wink,
and Lisa A. Ridnour

© Springer International Publishing Switzerland 2016
I. Batinić-Haberle et al. (eds.), *Redox-Active Therapeutics*,
Oxidative Stress in Applied Basic Research and Clinical Practice,
DOI 10.1007/978-3-319-30705-3_15

DOI 10.1007/978-3-319-30705-3_31

On Page 378, in line no-4, soluble guanylate cyclase is incorrectly captured. The correct format is as follows: soluble guanylate cyclase (SGC)

On Page 378, line no-4, cGMP is incorrectly captured. The correct format should be: cyclic guanosine monophosphate (cGMP)

On Page 379, under section 15.2 line no-6 it is given as “HER2” is incorrectly captured. The correct format is “human epidermal growth factor (HER2)”

On page 379, under section 15.2.1, line 26, it is given as “metal center” is incorrectly captured. The correct format should be “metal centers”

On Page 380, under section 15.2.1, line-36 “O₂ Concentration” is incorrectly captured. The correct format is “O₂ Concentrations”

The updated original online version for this chapter can be found at
http://dx.doi.org/10.1007/978-3-319-30705-3_15

On Page 380, under section 15.2.1, line 43 “function and” is incorrectly captured. The correct format is “function to”.

On Page 380, under section 15.2.1, line 51 it is (Cys 520 in human) is incorrectly captured. The correct format should be (Cys 520 in humans).

On Page 380, under section 15.2.1, line 54, it is given as 100 to 300 is incorrectly captured. The correct format should be “100 to 500”.

On Page 380, under section 15.2.1, line 58, it is given as “metastasis [76]” is incorrectly captured. The correct format should be “metastasis [76, 77].

On Page 384, the numbering style is 15.3.3 which was incorrectly captured. The correct format is 15.3.2.1.

On Page 385, the numbering style is 15.3.4 was incorrectly captured. The correct format is 15.3.2.2

On Page 386, the numbering is given as 15.3.5: The correct format should be changed to 15.3.2.3

On Page 387, the numbering is given as 15.3.6: The correct format is 15.3.3

On Page 387 under section: 15.3.3, HNO Donors and Their Potential Usage the text has been inserted:

“The role of HNO as a key pharmacological agent in the treatment of alcoholism, cardiovascular disease, and cancer has generated much interest. However, HNO chemical biology has been limited due to its irreversible dimerization, thus necessitating use of donor compounds for production of HNO in situ”

On Page 387 above “Angeli’s salt (AS, $\text{Na}_2\text{N}_2\text{O}_3$)” a new subheading needs to be added:

15.3.3.1 Diazeniumdiolate based HNO donors

On Page 387, under section: 15.3.3, line-10, it is incorrectly captured as “a structurally”. The correct format is “the structurally”

On Page 387, under section 15.3.3, line-11, it is given as “NO and HNO”. The correct format should be “NO and/or HNO”.

On Page 387, under section 15.3.3, line-10 “class of compounds known as” should be deleted. On Page 389, the numbering is 15.3.7:

The correct numbering should be changed to 15.3.3.2

On Page 390, the numbering is 15.3.8: The correct numbering should be 15.3.4

On page 391, the under 15.4 Conclusion below the line-11, “as novel therapeutic agents” the next paragraph is to be added:

Acknowledgement

This work was supported in part by the Intramural Research Program of the NIH, Cancer and Inflammation Program.